Dian-Jung Chiang, MD
Gastroenterology · Seattle, WANPI 1982870127
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Gilead at 53.5% of the total. 2025 is the largest year on record at $5,381, more than ten times the $128 reported in 2020.
Across 33 payments — averaging $303.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
- Ipsen Biopharmaceuticals, Inc$3K
- Mirum Pharmaceuticals, Inc.$1K
- Eisai Inc.$121
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$118
- Madrigal Pharmaceuticals$84
- plus $230 from 6 others
Across 6 payments — averaging $8009.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Pharma SAS$30K
- Bausch Health US, LLC$19K
What the payments were for
- Consulting fees$4,28043%
- Speaking & faculty fees$2,76028%
- Travel & lodging$1,62116%
- Food & beverage$1,34413%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 12 | $5,354 |
| Ipsen Biopharmaceuticals, Inc | 1 | $2,760 |
| Mirum Pharmaceuticals, Inc. | 5 | $1,337 |
| Eisai Inc. | 1 | $121 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $118 |
| Madrigal Pharmaceuticals | 2 | $84 |
| AbbVie | 5 | $83 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $51 |
| Novo Nordisk | 1 | $34 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,004 in reported general payments places this provider in the 85th percentile of 447 gastroenterology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Entecavir | 31 | $12,115 |
| Ursodiol | 43 | $5,303 |
| Spironolactone | 19 | $279 |
| LoperamideLoperamide Hcl | 17 | $95 |
| Omeprazole | 14 | $87 |
| Carvedilol | 17 | $55 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Seattle
- Kris KowdleySeattle$1.4M
- Scott LeeSeattle$220K
- Alyssa ChoiSeattle$102K
- Andrew RossSeattle$99K
- Shayan IraniSeattle$57K
- Laurens JanssensSeattle$56K
- George McDonaldSeattle$53K
- Adam TempletonSeattle$49K
- Sravanthi ParasaSeattle$47K
- Liam HilsonSeattle$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.